A foundry mix includes a major amount of a foundry aggregate and an effective binding amount of a binder system. The binder system cures in the presence of sulfur dioxide and a free radical initiator. The binder system may include (1) 10 to 70 parts by weight of an epoxy novolac resin; (2) 0.5 to 10 parts by weight of resorcinol; (3) 20 to 70 parts by weight of a monomeric or polymeric acrylate; and (4) an effective amount of a free radical initiator. Notably, (1), (2), (3) and (4) are separate components or mixed with another of said components, provided (4) is not mixed with (3) until a foundry mix is to be created, where said parts by weight are based upon 100 parts of the binder system.

A foundry mix includes a major amount of a foundry aggregate and an effective binding amount of a binder system. The binder system cures in the presence of sulfur dioxide and a free radical initiator. The binder system may include (1) 10 to 70 parts by weight of an epoxy novolac resin; (2) 0.5 to 10 parts by weight of resorcinol; (3) 20 to 70 parts by weight of a monomeric or polymeric acrylate; and (4) an effective amount of a free radical initiator. Notably, (1), (2), (3) and (4) are separate components or mixed with another of said components, provided (4) is not mixed with (3) until a foundry mix is to be created, where said parts by weight are based upon 100 parts of the binder system.

The present invention relates to a bio-based polyol comprising a thiol-epoxy reaction product of an epoxidized nut or seed oil derivative, and a thiol-containing reactant. The bio-based polyol of the present invention can then be combined with a diisocyanate or a polymeric isocyanate to create a polyurethane material.

The present invention relates to a bio-based polyol comprising a thiol-epoxy reaction product of an epoxidized nut or seed oil derivative, and a thiol-containing reactant. The bio-based polyol of the present invention can then be combined with a diisocyanate or a polymeric isocyanate to create a polyurethane material.

The disclosure is directed to cocrystals of fasoracetam, including R-fasoracetam, and various coformers. Crystalline materials comprising fasoracetam, including R-fasoracetam, are also provided. The disclosure further includes pharmaceutical compositions and methods of treatment of the cocrystals and crystalline materials of the disclosure.

The invention relates to a composition that contains a binary mixture of bisphenol F and propoxylated bisphenol F. The aim of the invention is to provide aromatic polyols for preparing polyurethane-based and polyisocyanurate-based polymers, which ensure good handling from a technical point of view and good miscibility with the isocyanate component and render the end product flameproof. For this purpose, the invention devises a composition, which contains a binary mixture of ethoxylated bisphenol F and propoxylated bisphenol F in a weight ratio of 20:80 to 80:20.

The invention relates to a composition that contains a binary mixture of bisphenol F and propoxylated bisphenol F. The aim of the invention is to provide aromatic polyols for preparing polyurethane-based and polyisocyanurate-based polymers, which ensure good handling from a technical point of view and good miscibility with the isocyanate component and render the end product flameproof. For this purpose, the invention devises a composition, which contains a binary mixture of ethoxylated bisphenol F and propoxylated bisphenol F in a weight ratio of 20:80 to 80:20.

The present invention pertains to the technical field of biomedicine, and relates to isopaucifloral F phosphate compounds and pharmaceutical uses thereof. It has been confirmed through experiments that said isopaucifloral F phosphate compounds and pharmaceutically acceptable salts thereof have effects on the bone remodeling process by exerting their anti-osteoporosis efficacy through a dual-mode mechanism of action of promoting osteogenesis and reducing osteoclast resorption, have the characteristics of high bioavailability, stable metabolism and good safety, and can be used to prepare a new generation of anti-osteoporosis drugs.

##STR00001##

The disclosure is directed to cocrystals of fasoracetam, including R-fasoracetam, and various coformers. Crystalline materials comprising fasoracetam, including R-fasoracetam, are also provided. The disclosure further includes pharmaceutical compositions and methods of treatment of the cocrystals and crystalline materials of the disclosure.

The rubber composition comprises at least one phenol/aldehyde resin based on:

at least one aromatic polyphenol comprising at least one aromatic ring bearing at least two hydroxyl functions in the meta position relative to one another, the two positions ortho to at least one of the hydroxyl functions being unsubstituted, and

at least one aldehyde of formula (A):

##STR00001##

in which:

X comprises N, S or O,

R represents —H or —CHO.